Nektar Therapeutics (NASDAQ:NKTR) Insider Jonathan Zalevsky Sells 10,300 Shares

Nektar Therapeutics (NASDAQ:NKTR) insider Jonathan Zalevsky sold 10,300 shares of the stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $1.01, for a total transaction of $10,403.00. Following the sale, the insider now directly owns 316,604 shares of the company’s stock, valued at $319,770.04. This represents a 3.15 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Jonathan Zalevsky also recently made the following trade(s):

• On Thursday, December 19th, Jonathan Zalevsky sold 51,115 shares of Nektar Therapeutics stock. The shares were sold at an average price of $0.94, for a total value of $48,048.10.

Nektar Therapeutics Price Performance

Nektar Therapeutics stock opened at $0.93 on Friday. The firm has a 50 day moving average price of $0.92 and a 200-day moving average price of $1.12. Nektar Therapeutics has a twelve month low of $0.63 and a twelve month high of $1.93.

Hedge Funds Weigh In On Nektar Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. JPMorgan Chase & Co. raised its position in shares of Nektar Therapeutics by 197.3% in the third quarter. JPMorgan Chase & Co. now owns 913,300 shares of the biopharmaceutical company’s stock valued at $1,187,000 after purchasing an additional 606,057 shares during the period. Peapod Lane Capital LLC bought a new position in shares of Nektar Therapeutics in the fourth quarter worth $1,030,000. Eventide Asset Management LLC lifted its holdings in Nektar Therapeutics by 24.8% during the 3rd quarter. Eventide Asset Management LLC now owns 9,400,000 shares of the biopharmaceutical company’s stock worth $12,220,000 after purchasing an additional 1,870,904 shares in the last quarter. State Street Corp increased its position in shares of Nektar Therapeutics by 11.9% during the third quarter. State Street Corp now owns 3,345,733 shares of the biopharmaceutical company’s stock valued at $4,349,000 after buying an additional 355,759 shares during the period. Finally, The Manufacturers Life Insurance Company bought a new stake in Nektar Therapeutics during the 3rd quarter worth approximately $86,000. 75.88% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. Piper Sandler started coverage on Nektar Therapeutics in a report on Monday, November 4th. They issued an “overweight” rating and a $7.00 target price on the stock. B. Riley assumed coverage on shares of Nektar Therapeutics in a research report on Wednesday, January 8th. They set a “buy” rating and a $4.00 target price for the company. Finally, HC Wainwright restated a “buy” rating and issued a $6.50 target price on shares of Nektar Therapeutics in a report on Monday, January 13th. Two analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $4.08.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.